GIBSON DUNN

Gibson Dunn Advises Arrowhead Pharmaceuticals on Asset Purchase Agreement Between Sanofi and Visirna Therapeutics

Firm News | August 11, 2025

Gibson Dunn is advising Arrowhead Pharmaceuticals on an asset purchase agreement between Sanofi and Visirna Therapeutics, a majority-owned subsidiary of Arrowhead. Under the terms, Sanofi will acquire rights to develop and commercialize investigational plozasiran in Greater China.

Led by partner Karen Spindler, our corporate team includes partner Jin Hee Kim and associates Paul Rafla and Sonari Chidi. Partners Pamela Lawrence Endreny and Benjamin Rapp and associate Ryan Rott are advising on tax; partner Cassandra Gaedt-Sheckter and associate Courtney Wang are advising on data privacy; and partner John Partridge and of counsel Ning Ning are advising on compliance.

Related People

Karen A. Spindler

Jin Hee Kim

Paul Rafla

Sonari Chidi

Pamela Lawrence Endreny

Ryan Rott

Cassandra L. Gaedt-Sheckter

Courtney Wang

John D.W. Partridge

Ning Ning

Related Capabilities

Mergers and Acquisitions

© 2026 Gibson, Dunn & Crutcher LLP. All rights reserved. For contact and other information, please visit us at www.gibsondunn.com. | **www.gibsondunn.com**